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Abstract
Rationale Spatial working memory is dependent on the ap-
propriate functioning of the prefrontal cortex (PFC). PFC ac-
tivity can be modulated by noradrenaline (NA) released by
afferent projections from the locus coeruleus. The coreuleo-
cortical NA system could therefore be a target for cognitive
enhancers of spatial working memory. Of the three classes of
NA receptor potentially involved, the α2 and α1 classes seem
most significant, though agents targeting these receptors have
yielded mixed results. This may be partially due to the use of
behavioural assays that do not translate effectively from the
laboratory to the clinical setting. Use of a paradigm with im-
proved translational potential may be essential to resolve these
discrepancies.
Objectives The objective of this studywas to assess the effects
of PFC-infused α2 and α1 adrenergic receptor agonists on
spatial working memory performance in the touchscreen con-
tinuous trial-unique non-matching to location (cTUNL) task
in rats.
Methods Young male rats were trained in the cTUNL para-
digm. Cannulation of the mPFC allowed direct administration
of GABA agonists for task validation, and phenylephrine and
guanfacine to determine the effects of adrenergic agonists on
task performance.
Results Infusion of muscimol and baclofen resulted in a
delay-dependent impairment. Administration of the α2 ago-
nist guanfacine had no effect, whilst infusion of theα1 agonist
phenylephrine significantly improved working memory
performance.
Conclusions Spatial working memory as measured in the rat
cTUNL task is dependent on the mPFC. Enhancement of nor-
adrenergic signalling enhanced performance in this paradigm,
suggesting a significant role for the α1 receptor in this
facilitation.
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Introduction
Among the many cognitive functions for which it is important,
the medial prefrontal cortex (mPFC) is perhaps most closely
associated with working memory, defined as the ability to
transiently maintain and manipulate task-relevant information
in a temporary buffer to guide performance (Arnsten et al.
1998; De Luca et al. 2003; Arnsten 2006). Support for a role
for the PFC in working memory includes the identification of
‘delay neurons’ in the PFC which fire during the delay between
the sample phase and the response (Fuster and Alexander 1971;
Kubota and Niki 1971), the observation that these neurons have
been shown to represent specific locations within the visual
field (Funahashi et al. 1989), and the finding that damage to
PFC can lead to delay-dependent impairments in working
memory (Dunnett 1990; Seamans et al. 1995; Floresco et al.
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1997). Understanding the neurobiological mechanisms by
which this structure performs such critical functions is essential
both from the perspective of correcting aberrant activity in the
context of physical or pathological insult, as well as in enhanc-
ing otherwise normal activity.
The catecholamine systems have long been known to play
a central role in the regulation of prefrontal-dependent work-
ing memory. Catecholamine depletion of both dopamine and
NA disrupts working memory performance to a level compa-
rable to that observed following a prefrontal lesion, although
performance is unaffected if dopamine depletion is reduced
from 87 to 56 % (Brozoski et al. 1979). Coull et al. (1995)
found that the mixed α1-α2 agonist clonidine dose-
dependently affected CANTAB spatial working memory per-
formance, with significant improvement at a higher dose of
clonidine, although which receptor was responsible for this
effect is unclear. Subsequently, the α2-R agonist guanfacine,
though not clonidine, was found to improve performance on
the same task (Jäkälä et al. 1999; see Chamberlain et al. 2006
for a review). It has since been established that pharmacolog-
ical modulation of prefrontal noradrenergic receptors can bi-
directionally shift working memory performance based on the
specific receptor sub-type targeted. Indeed, the α1 and α2
noradrenergic receptors (R) have been postulated to have op-
posing roles within the PFC (Arnsten 1997; Arnsten et al.
1998), with high affinity α2-R activation improving and
low-affinity α1-R stimulation impairing PFC function
(Arnsten 2000; Robbins and Arnsten 2009). One interpreta-
tion of these findings (Arnsten 2000) is that higher levels of
NA release, that activate α1-receptors, are associated with
stress that impairs spatial working memory according to an
inverted U-shaped function.
Functional consequences of noradrenergic receptor en-
gagement can also be influenced by other factors such as
baseline NA levels and the level of arousal at the time of drug
administration (Arnsten 2000; Birnbaum et al. 2004; Robbins
and Arnsten 2009). For example, whilst the α2-R agonists
clonidine and guanfacine have both been shown to improve
performance on delayed response tasks (Mao et al. 1999;
Avery et al. 2000), the majority of studies in which facilitation
was detected used rodent or monkey models of age- or exper-
imentally induced catecholamine depletion (e.g. Arnsten and
Goldman-Rakic 1985, 1990; Arnsten et al. 1988; Tanila et al.
1996). Similarly, whilst α2-R agonist-induced facilitation
can be reversed with an α2-R antagonist (Arnsten and
Goldman-Rakic 1985) and α2-R antagonist administra-
tion to the primate dorsolateral prefrontal cortex impairs
delay-dependent spatial working memory (Li and Mei
1994), the α2-R antagonist atipamezole has been found
to facilitate prefrontal-dependent attentional set shifting
(Lapiz and Morilak 2006) and attentional measures in
the stop signal reaction time task (Bari and Robbins
2013) in the rat.
Pharmacological manipulation of the α1 receptor has
yielded equally divergent results, with agonists found to both
impair (Arnsten et al. 1999; Mao et al. 1999) and facilitate
(Doze et al. 2011) spatial working memory performance. In
addition, α1 antagonists have been found to depress baseline
or reverse facilitated performance in a number of paradigms,
suggesting a potential role for this receptor sub-type in en-
hancement of prefrontal-dependent cognition (Lapiz and
Morilak 2006; Bari and Robbins 2013).
This study investigated the prefrontal adrenergic contribu-
tion to delay-dependent spatial working memory performance
in the touchscreen cTUNL task (Oomen et al. 2015) in young,
healthy rats. The contribution of the mPFC to task perfor-
mance is unknown. Performance in cTUNL is dependent on
the dorsal dentate gyrus of the hippocampus (Oomen et al.
2015), but this effect was found to be independent of the delay
condition between trials. The first experiment in the present
study, however, confirmed that the mPFC supports delay-
dependent performance in the cTUNL task using localised
microinfusion of GABAergic agonists, validating a mPFC-
dependent working memory deficit. Therefore, cTUNL can
be used to dissociate dentate gyrus and mPFC dysfunction,
by manipulating the delay condition between trials. In this
study, cTUNL was used to assess adrenergic modulation of
performance by using the α2 agonist guanfacine and the α1
agonist phenylephrine. Guanfacine was chosen due to its role
as a putative cognitive enhancer in the context of normal and
pathological ageing, as well as attention deficit hyperactivity
disorder (ADHD; Hunt et al. 1985; Arnsten et al. 2007). How-
ever, to our knowledge, no studies have yet assessed the effi-
cacy of this compound in non-catecholamine depleted rats.
Phenylephrine was selected to further investigate the potential
role of the α1 receptor in prefrontal function, with recent
evidence indicating a function for this receptor in mediating
the cognitive enhancing effects of the atypical psychomotor
stimulant modafinil in humans (Winder-Rhodes et al. 2010).
Materials and methods
Subjects
Nine (experiment 1), 18 (experiment 2a) and 14 (experiment
2b) experimentally naïve male Lister Hooded rats (Harlan,
UK) weighing a mean of 320 g (range 302–336 g) at the
commencement of behavioural training served as subjects.
At the time of drug administration, rats were 6–7 months of
age. Rats were housed in groups of 4 in a temperature and
humidity controlled room, under a 12-h alternating light/dark
cycle (lights off, 07:00). Behavioural testing was conducted
during the dark phase. Ad libitum access to water was provid-
ed throughout. One week following delivery, food was re-
stricted to maintain no less than 85 % of free-feeding weight
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throughout the entire experiment. All procedures were con-
ducted in accordance with the United Kingdom Animals
(Scientific Procedures) Act, 1986.
Behavioural apparatus
The behavioural apparatus consisted of 12 trapeze-shaped op-
erant chambers [Campden Instruments, UK; 30 cm (height)
x 33 cm (length)x 25 cm (width at screen) or x 13 cm (width at
magazine)] described elsewhere (Horner et al. 2013). Briefly,
chambers consisted of black Perspex walls, a perforated metal
grid floor, a transparent lid and a 15-in. touch-sensitive LCD
monitor. The touchscreen was covered with a black Perspex
mask (35.8 hx 28 w) with 15 response windows (3 rows of 5
locations). Response windows were 3.3 x 3.3 cm in size,
spaced 1.5 cm apart (lowest row 1.5 cm from the floor). A
food magazine equipped with a LED light and infrared beams
was situated opposite the touchscreen. This was connected to
an externally located pellet dispenser which provided palat-
able food reinforcement (45 mg 5-TUL AIN-76A dustless
pellets (TestDiet, Indiana, USA)) during cTUNL perfor-
mance. A click and tone generator and a LED house light were
mounted on a shelf above the behavioural arena. Each operant
chamber was individually enclosed within a sound attenuating
outer box. The behavioural task was controlled by in-house
code written in ABET II software (Lafayette Instruments Ltd.,
USA) running on an Intel E5200 Dual Core Pentium
(2.5 GHz) computer. Each chamber was also equipped with
infrared beam arrays at the front and rear of the arena to mon-
itor animal activity and an infrared camera to allow visual
inspection of behaviour.
cTUNL training
A detailed overview of the cTUNL paradigm is provided else-
where (Oomen et al. 2015). Briefly, at the start of each session,
a single screen location is illuminated with a white square (S+)
which must be touched to earn a reward. After a variable
delay, the same location (S-) is presented alongside a novel
location (S+). The animal must non-match to location by
touching the new S+, with the previously correct location
becoming the incorrect location on the next trial (see Fig. 1),
which continues throughout the rest of the session. Stimuli
remain on the screen until the animal has made a response.
The spatial separation between the target (S+) and sample (S-)
was defined as the number of empty locations between
stimuli.
For both cohorts of rats, the same training protocol was
implemented. The pre-training stage (to establish familiarity
with the touchscreen chamber and a basic instrumental re-
sponse) is identical to that of TUNL,which has been described
in detail elsewhere (Oomen et al. 2013). For cTUNL task
acquisition, rats received 14 days of 1-h training sessions
(max 98 trials) with a fixed inter-trial interval (ITI) of 2 s. Rats
were trained until individual performance reached a pre-set
criterion of 65% correct for two consecutive sessions (exclud-
ing correction trials). Once acquired, rats were rested and re-
tested weekly until surgery to avoid overtraining.
Following recovery from surgery, rats were re-baselined on
the task with a 2-s fixed ITI/delay (due to the continuous
nature of the task, the time period between one trial and the
next can be classified as both a delay and an ITI. It will be
referred to as a delay in this study). After reaching pre-surgery
performance levels, rats were transferred to a schedule in
which only separations 1 and 3 (i.e. 1 or 3 empty locations
between stimuli only, with no trials presented of separations 0
or 2; see Fig. 1) were used, with a variable delay of 1 and 6 s.
The elimination of separation 0 and 2 trials reduced the num-
ber of conditions for statistical analysis and was chosen on the
basis that the full range of spatial separations is theoretically
more relevant to a hippocampal manipulation (Oomen et al.
2015) than the prefrontal focus of this study. The variable
delay was introduced to tax working memory. Training con-
tinued until a criterion of two consecutive sessions at 65 %
correct trial performance (averaged across separations) was
reached.
Fig. 1 A schematic example of four potential trials of the cTUNL task.
The non-matching to location rule is maintained throughout. The novel
location (S+) on the previous trial becomes the familiar (S-) location on
the next trial. Separation can be manipulated by varying the number of
empty squares between stimuli (i.e. trials 2 and 3 are separation 1 trials,
whilst trial 4 is a separation 3 trial). Variable delays can be implemented
between trials
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Surgical procedures
All rats received bilateral implantation of 22-gauge indwelling
guide cannulas under deep isoflurane-induced anaesthesia.
Animals were secured in a stereotaxic frame, and the skull
was exposed by an incision along the scalp. This was followed
by a craniotomy, after which the guide cannulae (3 mm below
pedestal) were implanted at the following stereotaxic coordi-
nates: anteroposterior, 3.2 mm; lateral, 0.75 mm (both from
bregma); dorsoventral, −2.0 mm (from dura; Paxinos and
Watson 2013). Three jeweller screws and dental cement se-
cured the cannulae. Obdurators sat flush with the guide can-
nulae and remained in place throughout except during infu-
sions. After surgery, the scalp incision was sutured and post-
operative analgesia (metacam; 0.75 mg/0.15 mls.c) and warm
saline (37 °C; 0.5 mls.c) were administered. Rats were placed
in singularly housed heated cages in a dark room overnight,
with ad libitum access to water and food after anaesthetic
recovery. Ad libitum food and water access continued for
7 days postoperatively before animals were returned to behav-
ioural testing (with food restriction). Rats were singularly
housed for the remainder of the experiment to avoid cannula
damage.
Infusion procedure
An experimental timeline is provided in Fig. 2. Rats were
habituated to infusions with a session in which
the infusion needle was lowered into the cannulae follow-
ed a day later by a session in which an infusion of vehicle
(at comparable volume and rate to the experimental infu-
sions) was given. Following dose pilot infusions, rats in
experiment 1 received bilateral infusions of vehicle or a
cocktail of the GABAA receptor agonist muscimol
(0.00825 nmol/0.3 μl, Sigma-Aldrich, UK) and the
GABAB receptor agonist baclofen (0.0825 nmol/0.3 μl,
Sigma-Aldrich, UK). These doses were selected on the
basis of pilot infusions in which higher concentrations
were found to be sedative (data not shown).
Rats in experiment 2a received bilateral infusions of vehi-
cle (0.5 μl saline, 0.9 %), guanfacine hydrochloride (0.01 μg/
0.5 μl or 0.1 μg/0.5 μl in 0.9 % saline, Sigma-Aldrich, UK) or
phenylephrine hydrochloride (0.01 μg/0.5 μL or 0.1 μg/
0.5 μL in 0.9 % saline, Sigma-Aldrich, UK). Doses for phen-
ylephrine were adopted from (Arnsten et al. 1999).
Guanfacine doses were based on Ramos et al. (2006) and
increased 100–1000-fold in accordance with the findings of
Franowicz and Arnsten (1998) and Avery et al. (2000) which
suggested that higher guanfacine doses were required in non-
catecholamine depleted animals. Given the limited number of
microinfusions possible prior to causing tissue damage at the
infusion site, a follow up study (experiment 2b) used a wider
range of guanfacine doses (0.001 μg/0.5 μl, 0.0001 μg/0.5 μl,
0.00001 μg/0.5 μl in 0.9 % saline) compared to vehicle (0.9%
saline) but did not extend the dose range for phenylephrine
due to the establishment of an effective dose within the initial
dose range. Higher doses were not used based on pilot work
indicating a sedative effect (data not shown).
For both experiments, infusions were administered in a
counterbalanced, within-subjects design to prevent learning
effects interfering with potential drug effects. Rats were
assigned to counterbalanced groups based on the number of
days required to reach criterion (65 % correct overall) on the
post-surgery testing schedule (including separations 1 and 3
only, and delays of 1 or 6 s). A latin square design was used to
ensure equal numbers of rats received each dose condition on
any given infusion day, with no rats receiving each dose con-
dition in the same order of infusions. Rats were mildly re-
strained, the infusion cannula (28 gauge) lowered into the
guides for 1 min pre- and post-infusion. Simultaneous bilater-
al infusions were administered via two 10-μl Hamilton syrin-
ges linked to the cannula via propylene tubing. A precision
syringe pump (Harvard Apparatus, Inc.) drove the syringes at
a flow rate of 0.15 μL/min (experiment 1) or 0.25 μL/min
(experiment 2). Rats were tested within 10 min of infusions.
A 48-h washout period was implemented between each infu-
sion, during which one testing session was administered.
Histology
Following completion of behavioural testing, rats were deeply
anaesthetised (0.2 ml pentobarbital, i.p.) and transcardially
perfused with 0.1 M phosphate-buffered saline followed by
neutral-buffered formalin (NBF). Brains were post-fixed in
NBF, transferred to 30 % sucrose in dH2O and, once
cryoprotected, sliced into 60-μm sections using a cryostat.
Sections were stained with Cresyl Violet for placement assess-
ment, verified using a reference atlas (Paxinos and Watson
2013). Whilst it is acknowledged that the mPFC constitutes
a range of subregions associated with specific functional and
anatomical features such as the division between the medial
(medial precentral, dorsal anterior cingulate areas and dorsal
part of prelimbic cortex) and the ventral mPFC (ventral
prelimbic cortex, infralimbic cortex and medial orbital areas;
Heidbreder and Groenewegen 2003), the current study did not
aim to differentiate and compare functions across different
subregions. Therefore, individual rats were only excluded if
placements were outside the mPFC, defined as the combined
medial and ventral mPFC (Heidbreder and Groenewegen
2003).
Analysis and statistics
Task accuracy was the main dependent variable, expressed as
the percentage of correct responses [(correct trials/total trials)
x 100] excluding correction trials. Prior to analysis, all data
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points were converted to z scores to identify potential outliers,
defined as values more than ±2.5 standard deviations away
from the mean. As recommended by Field (2013), outliers
were removed and replaced with the group mean ±2 standard
deviations (i.e. the extremity of the outlier was reduced from
±2.5 to ±2 standard deviations away from the mean). The
modified % correct score was then used for statistical analysis.
In experiment 1 and 2b, no outliers were detected. In experi-
ment 2a, three outliers were detected and replaced in the
guanfacine data set. In the phenylephrine data set, four outliers
were detected and replaced. Note that there were 12 individual
mean % correct scores associated with each rat (drug [high,
low, vehicle] * separation [1 and 3] * delay [1 and 6 s]) in a
data set of 18 rats, resulting in a total of 216 mean values, of
which a maximum of 4 were identified as outliers within a
single data set (the phenylephrine data set).
Latency scores on individual trials exceeding 5 s were
excluded, and the median value across the session was
used for analysis. Repeated measures ANOVA were used
with separation, delay and drug as within-subject factors.
Significant interactions were followed up using Sidak’s
correction.
Results
Histology
An overview of mPFC cannula locations for experiment 1
(muscimol-baclofen cocktail) is presented in Fig. 3. One rat
was excluded from this study due to compromised tissue. A
similar overview of cannula locations for experiment 2 (phen-
ylephrine and guanfacine) is presented in Fig. 4. No rats were
excluded from this experiment.
Infusion of muscimol-baclofen into mPFC disrupts
cTUNL performance at long delays
High concentrations of muscimol and baclofen (0.033 and
0.33 nmol, respectively) led to sedative effects resulting in
a lack of trial completion (data not shown). Lowering the
concentration (muscimol = 0.0165 nmol, baclofen =
0.165 nmol) led to a non-specific reduction in percentage
correct across long and short delays (data not shown).
Using further reduced concentrations of 0.00825 and
0.0825 nmol for muscimol and baclofen, respectively, a
drug by delay interaction was identified, in which rats per-
formed significantly worse following infusion of muscimol
and baclofen compared to vehicle specifically when the
delay was long (F(1,7)=7.718, p=0.027; see Fig. 5). A
main effect of delay (F(1,7)=31.888, p=0.001) and sepa-
ration (F(1,7)=40.373, p=0.0001) was also observed, in
which performance was significantly higher when delays
were short (p=0.0001) and separations were large (p=
0.0001). Animals completed all trials within a session, on
all infusion conditions, and no differences in latencies were
observed (Table 1). Performance during washout period
(76.0±1.8) did not differ from that on the vehicle-infused
day (73.4±1.8, p>0.05).
Fig. 2 A schematic overview of the experimental procedure adopted for
experiment 1 (muscimol+baclofen cocktail vs. vehicle) and experiment 2
(phenylephrine and guanfacine vs. vehicle). The two experiments used
two different cohorts of rats. B=one (or more) baseline test sessions (no
infusion).Drop=habituation session where the infusion needle is lowered
into the cannula, but nothing is infused, followed by behavioural testing.
Vehicle infusion=habituation infusion followed by behavioural testing.
LS=latin square counterbalanced infusion design with one baseline test
session in between each infusion day. For the dose pilots in experiment 1,
all rats received two infusions (one vehicle, one muscimol+baclofen
cocktail). The difference between LS1 and LS2 in experiment 1 is
changes to the behavioural parameters of the task. For the dose pilot in
experiment 2, all rats received one infusion only (between subjects
design). The data presented is based on LS2 (muscimol+baclofen
cocktail vs. vehicle) for experiment 1 (n=9). For experiment 2a, data is
based on LS1 (phenylephrine and guanfacine vs. vehicle, n=18), and LS2
for experiment 2b (guanfacine vs. vehicle follow up, n=14). There was a
reduction in the n numbers between experiments 2a and b due to cannulae
loss
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Infusion of phenylephrine into mPFC enhances cTUNL
performance
Analysis of the five microinfusion conditions [vehicle, low
(0.01 μg/0.5 μL) and high (or 0.1 μg/0.5 μL) doses of phen-
ylephrine as well as low (0.01 μg/0.5 μl) and high (0.1 μg/
0.5 μl) concentrations of guanfacine] revealed a significant
interaction between drug, delay and separation (F(4,68)=
2.622, p=0.042). This interaction was driven by phenyleph-
rine, as a separate analysis of the two phenylephrine doses
and the vehicle infusion also resulted in a significant three-
way interaction of drug, delay and separation (F(2,34)=
3.819, p=0.032). Planned pairwise comparisons revealed that
the percent correct scores were significantly improved follow-
ing the low dose of phenylephrine compared with vehicle on
long delay trials when the separation was large (p=0.039; see
Fig. 6). There was no main effect of drug. As expected, a
significant main effect of delay (F(1,17)=52.302, p=0.0001),
separation(F(1,17)=49.627, p=0.0001) and a delay and sepa-
ration interaction (F(1,17)=20.078, p=0.0001) was revealed;
percent correct performance was significantly higher at 1 ver-
sus 6 s delays (p=0.0001) and at large versus small separation
trials (p=0.0001). The number of trials completed did not differ
between infusion conditions (the low phenylephrine dose saw
the lowest trial completion rate at 98.2 % completion). No
differences in latencies were observed (Table 2).
BAFig. 3 Histology for experiment
1 (muscimol-baclofen cocktail). a
Schematic of sections of the rat
brain (adapted from Paxinos and
Watson 2013) displaying the
location of placements for rats
infused with muscimol-baclofen
cocktail. The numbers represent
the mm distance from bregma. b
Example of Cresyl Violet stained
section displaying the location of
the guide cannula
BA
Fig. 4 Histology for experiment
2 (phenylephrine/guanfacine). a
Schematic of sections of the rat
brain (adapted from Paxinos and
Watson 2013) displaying the
location of placements for rats
infused with guanfacine and
phenylephrine. The numbers
represent the mm distance from
bregma. b Example of Cresyl
Violet stained section displaying
the location of the guide cannula
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Infusions of guanfacine into mPFC failed to affect cTUNL
performance
An initial 1-day pilot was undertaken to assess the suitability
of the guanfacine doses 0.01 μg/0.5 μl, 0.1 μg/0.5 μl and
1.0 μg/0.5 μl based on the possibility of this compound in-
ducing sedative effects. The highest dose prevented trial com-
pletion, and this dose was therefore not used subsequently
(data not shown).
Performance during intra-mPFC microinfusions of
low (0.01 μg/0.5 μl) and high (0.1 μg/0.5 μl) doses
of guanfacine did not differ from vehicle infusions
(Fig. 7). There was no significant effect of drug nor
an interaction of drug with delay or separation. As ex-
pected, a significant main effect of delay (F(1,17)=
55.351, p=0.001), separation (F(1,17)=50.576, p=
0.0001) and a delay and separation interaction (F(1,
17)=7.456, p=0.014) was revealed; percent correct per-
formance was significantly higher at 1 versus 6 s delays
(p=0.0001) and at large versus small separation trials
(p=0.0001). Animals completed all trials within a ses-
sion, on all infusion conditions, and no differences in
latencies were observed (Table 2). Performance during
washout period (71.9±1.0) did not differ from that on
the vehicle-infused day (72.3±1.8, p>0.05).
The follow up study with a lower range of guanfacine
doses did not reveal any significant effects of microinfusions
of guanfacine compared to vehicle (Fig. 8). As before, a main
effect of delay (F(1,12)=124.908, p=0.0001) and separation
(F(1,12)=43.086, p=0.0001) was observed, in which perfor-
mance was higher on short delays (p=0.0001) and large
Fig. 5 Effect of muscimol and baclofen mPFC microinfusion on
performance across delays (1 and 6 s) and separations (1 and 3).
Performance on 6-s delay trials was significantly impaired following
muscimol and baclofen infusions compared to vehicle. ***p<.001, n=
9. Repeated measures ANOVAwith drug, separation and delay as within-
subject variables (Sidak’s correction). Error bars±SEM
Table 1 Latency to respond in experiment 1 (muscimol-baclofen
cocktail). The group average of the individual median correct response
latency, incorrect latency and reward response latency for infusion
sessions is presented in seconds. There were no significant differences
in correct (F(3,39)=0.445, p=0.723), incorrect (F(1,7)=1.008, p=0.349)
or reward collection latency (F(1,7)=0.824, p=0.394)
Infusion Correct response Incorrect response Reward collection
Mean SEM Mean SEM Mean SEM
Vehicle 1.491 0.092 1.832 0.106 1.326 0.054
Muscimol+baclofen cocktail 1.514 0.093 1.770 0.140 1.372 0.054
Fig. 6 Effect of phenylephrine mPFC microinfusions on performance
across delays (1 and 6 s) and separations (1 and 3). Performance on 1-s
delay trials was not influenced by phenylephrine infusions (a). Perfor-
mance on 6-s delay trials was significantly higher when the separation
was large compared to vehicle (b). *p<.05, n=18. Repeated measures
ANOVA with drug, separation and delay as within-subject variables
(Sidak’s correction). Error bars±SEM
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separations (p=0.0001). The number of trials completed did
not differ between infusion conditions (the low guanfacine
dose saw the lowest trial completion rate at 99.0 % comple-
tion). No differences in latencies were observed (Table 3).
Performance during washout period (74.7±0.8) did not differ
from that on the vehicle-infused day (74.9±1.3, p>0.05).
Discussion
The present experiments aimed to test whether the cTUNL
task, like TUNL (McAllister et al. 2013), is sensitive to
Table 2 Latency to respond in experiment 2a (phenylephrine and
guanfacine vs vehicle). The group average of the individual median
correct response latency, incorrect latency and reward response latency
for infusion sessions is presented in seconds. There were no significant
differences in correct (F(4,68)=1.166, p=0.334), incorrect (F(4,68)=
1.002, p=0.413) or reward collection latencies (F(4,68)=0.441, p=
0.778)
Infusion Correct response Incorrect response Reward collection
Mean SEM Mean SEM Mean SEM
Vehicle 1.822 0.097 2.081 0.112 1.528 0.048
Guanfacine low 1.697 0.087 2.030 0.088 1.518 0.053
Guanfacine high 1.798 0.086 1.902 0.078 1.494 0.038
Phenylephrine low 1.741 0.088 2.098 0.092 1.514 0.056
Phenylephrine high 1.813 0.085 2.030 0.082 1.495 0.044
Fig. 7 Effect of guanfacinemPFCmicroinfusions on performance across
delays (1 and 6 s) and separations (1 and 3). Performance on neither 1-s
delay trials (a) nor 6-s delay trials (b) was affected by guanfacine infu-
sions. N=18. Repeated measures ANOVAwith drug, separation and de-
lay as within-subject variables (Sidak’s correction). Error bars±SEM
Fig. 8 Effect of follow up doses of guanfacine mPFC microinfusions on
performance across delays (1 and 6 s) and separations (1 and 3).
Performance on neither 1-s delay trials (a) nor 6-s delay trials (b) was
affected by lower guanfacine infusions. N=14. Repeated measures
ANOVA with drug, separation and delay as within-subject variables
(Sidak’s correction). Error bars±SEM
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prefrontal dysfunction, as well as to investigate the effects of
local adrenergic system modulation on task performance by
administration of the α2 receptor agonist guanfacine and the
α1 receptor agonist phenylephrine in healthy, young rats.
Temporary mPFC inactivation by the GABA agonists
muscimol and baclofen resulted in an expected delay-
dependent performance deficit, in which performance was
unaffected at short delays. Guanfacine did not alter behaviour,
whilst administration of low doses of phenylephrine signifi-
cantly improved performance. This was specific to trials
where working memory was taxed through long delays, and
stimulus separation was large. On these large separation trials,
there may be reduced need for hippocampal-dependent pattern
separation processes, as the similarity between the locations
represented is low (Talpos et al. 2010; McAllister et al. 2013).
This perhaps makes some sense given that the hippocampus,
and not mPFC, is required when separations are small (and
delay is short) on a similar touchscreen task (Talpos et al.
2010; McAllister et al. 2013). It is worth nothing that there
were no observed changes in latencies to respond or collect
rewards following any manipulation nor was trial completion
affected. In addition, performance was never altered when
working memory was not taxed (1 s delay condition), demon-
strating normal knowledge of the non-matching rule, as well
as a lack of gross motor or motivational changes influencing
task performance.
The current study is, to our knowledge, the first demonstra-
tion of a cognitive enhancing effect of phenylephrine. This
finding contrasts with that of Arnsten et al. (1999) in which
mPFC administration resulted in an impairment on delayed
alternation performance in the T-maze in young rats. Howev-
er, the delay was not manipulated within each animal in
Arnsten et al. (1999), but rather maintained at an individual
length for each rat in order to achieve a uniform performance
level of 80 %. These discordant results may therefore be due
to the differential taxing of working memory in the two stud-
ies. Our finding of a putative cognitive enhancement via en-
gagement ofα1 receptors is consistent with the dependence of
some of the cognitive enhancing effects of modafinil on this
sub-type (Duteil et al. 1990; Lin et al. 1992; Stone et al. 2002).
It is particularly notable that the phenylephrine-mediated ef-
fect in this study was detected in the most challenging delay
condition as administration of the α1 antagonist prazosin re-
versed the cognitive enhancing effects of modafinil on the
One-Touch Stockings of Cambridge planning task only at
the most challenging task manipulations. This is suggestive
of a role for the α1 receptors in the mediation of enhanced
cognitive function (Winder-Rhodes et al. 2010) under relative-
ly specific conditions of cognitive demand. Such findings are
probably also relevant to recent findings of improved CAN-
TAB spatial working memory performance following
modafinil in healthy volunteers (Müller et al. 2013) and pa-
tients with schizophrenia (Scoriels et al. 2012).
Optimal levels of PFC NA enhance working memory via
persistent delay-related neuronal firing (Fuster and Alexander
1973; Funahashi et al. 1989; Courtney et al. 1998; Zarahn
et al. 1999; Postle et al. 2000). A recent set of experiments
found that NA evoked persistent neuronal firing in the PFC
through α1 receptors when examining NA effects on pyrami-
dal neurons using combined patch clamp recordings and
optogenetics in acute brain slices. Phenylephrine application
induced long-lasting, persistent PFC pyramidal neuronal fir-
ing, whilst the application of prazosin blocked the NA-evoked
persistent response. In contrast, the α2 agonist clonidine did
not induce long-lasting, persistent PFC pyramidal neuronal
firing, whilst the α2 antagonist yohimbine partially blocked
NA-evoked persistent firing (Zhang et al. 2013). Clearly, there
is a need for further investigation of the conditions under
which stimulation of α1 receptors is cognitively beneficial
and the extent to which this can be demonstrated across spe-
cies using translational tasks assessing prefrontal function.
The lack of a cognitive enhancing effect of guanfacine in
this study may appear surprising given the status of this com-
pound as a putative cognitive enhancer. However, the baseline
level of NE signalling in the young, healthy animals used in
these experiments may account for this discrepancy. Specifi-
cally, whilst mostly beneficial effects of guanfacine adminis-
tration have been reported in aged species with naturally oc-
curring catecholamine depletion, less beneficial effects have
been demonstrated in young animals with intact
Table 3 Latency to respond in experiment 2b (guanfacine vs vehicle).
The group average of the individual median correct response latency,
incorrect latency and reward response latency for infusion sessions is
presented in seconds. There were no significant differences in correct
(F(3,39)=0.445, p=0.723), incorrect (F(3,39)=0.239, p=0.871) or
reward collection latencies (F(3,39)=0.159, p=0.923)
Infusion Correct response Incorrect response Reward collection
Mean SEM Mean SEM Mean SEM
Vehicle 1.713 0.094 2.012 0.084 1.479 0.049
Guanfacine low 1.800 0.059 2.017 0.097 1.496 0.039
Guanfacine middle 1.733 0.104 1.959 0.105 1.499 0.038
Guanfacine high 1.702 0.085 1.927 0.091 1.480 0.043
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catecholamine systems. For example, in aged monkeys, sys-
temic and centrally administered guanfacine (Arnsten et al.
1988; Arnsten and Goldman-Rakic 1990; Rämä et al. 1996,
Arnsten 1997), medetomidine (Rämä et al. 1996) and cloni-
dine (Arnsten and Goldman-Rakic 1990) have been demon-
strated to improve spatial working memory task performance.
Similarly, systemic administration of medetomidine (Carlson
et al. 1992) and microinfusions of guanfacine (Ramos et al.
2006) or medetomidine (Tanila et al. 1996) into the prelimbic
cortex of aged rats enhanced spatial working memory perfor-
mance (although see Sirviö et al. 1992 and Decamp et al. 2011
for a lack of enhancement in aged rats and monkeys respec-
tively). However, the same improvements have not been dem-
onstrated in young adult rats (Carlson et al. 1992; Tanila et al.
1996).
In the context of younger animals, sensitivity to enhance-
ment through systemic administration of clonidine has been
achieved in monkeys following catecholamine depletion ei-
ther specific to the PFC (Arnsten and Goldman-Rakic 1985)
or more globally (Cai et al. 1993). In the absence of lowered
baseline NA firing, infusions of guanfacine into dorsolateral
PFC in young healthy monkeys (Mao et al. 1999) and
guanfacine in human volunteers (Jäkälä et al. 1999; Swartz
et al. 2008) facilitates spatial working memory performance.
However, in cases where cognitive enhancement has been
demonstrated via systemic α2 agonists, higher doses than
those used with aged or catecholamine depleted animals are
required in order for enhancement to be observed (Jackson
and Buccafusco 1991; Franowicz and Arnsten 1998;
Franowicz and Arnsten 1999; Li et al. 1999; Avery et al.
2000). Some studies have reported no effects of theα2 agonist
medetomidine in young control rats, whilst reporting benefi-
cial effects with aged rats in the same experiment; such find-
ings emphasise the importance of age-related catecholamine
depletion in the effectiveness of α2 agonism (Carlson et al.
1992; Tanila et al. 1996). If α2 agonist-induced facilitation of
performance is related to the chronic central monoaminergic
and cholinergic depletion in aged rats, and thus an unregulated
sensitivity at PFC α2 receptor sites in the aged species (Luine
and Hearns 1990; Luine et al. 1990), it is possible that an
enhancement in performance of rats on cTUNL could be ob-
served under more challenging task parameters (such as an
increase in the delay), or through the use of natural or exper-
imentally induced catecholamine depletion.
As with the previous report of mPFC infused
phenylephrine-driven impairments in rats (Arnsten et al.
1999), the only study in which guanfacine has previously been
infused into the (aged) rat mPFC and yielded a cognitive en-
hancement also assessed behaviour using the T-maze (Ramos
et al. 2006). The difference in the tasks used in these and the
current study could be a significant contributor to the discor-
dant findings. The restriction of only two locations within the
T-maze may promote the use of idiothethic strategies rather
than spatial strategies to solve the task, which may reduce the
demand on spatial working memory. In contrast, the cTUNL
paradigm utilises 15 potential response locations, minimising
the utility of alternative and/or mediating strategies to reduce
working memory load during the delay. It is possible that the
T-maze and the cTUNL task differ in their sensitivity to
prefrontally mediated working memory processes under cer-
tain conditions, potentially resulting in a different functional
response to noradrenergic receptor engagement.
In summary, this study presents the first demonstration of a
cognitive enhancing effect of phenylephrine on spatial work-
ing memory and highlights the potential for targeting the α1
receptor for facilitation of performance in the context of a
young and healthy prefrontal cortex. This was achieved using
a novel touchscreen paradigm for measuring spatial working
memory in rodents, validated as sensitive to prefrontal inacti-
vation in a delay-dependent manner, and thus illustrating the
capacity of the task to detect both facilitation and impairment
of prefrontally mediated cognition.
Acknowledgments The work leading to these results has received
funding from the Innovative Medicines Initiative Joint Undertaking
(IMI) under grant agreement no. 115008. IMI is a public-private partner-
ship between the European Union and the European Federation of Phar-
maceutical Industries and Associations. CJH was funded by Wellcome
Trust grant 089703/Z/09/Z. The authors thank Friederike Preusser and
Natalie Busch for valuable assistance with behavioural testing in
experiment 1.
Disclosures TWR Consults for Cambridge Cognition, E. Lilly,
Lundbeck, Teva, Shire Pharmaceuticals, Otsuka. Research grants from
Lilly and Lundbeck. Royalties from Cambridge Cognition (CANTAB).
TJB and LMS consult for Campden Instruments Ltd.
References
Arnsten AF (1997) Catecholamine regulation of the prefrontal cortex. J
Psychopharmacol Oxf Engl 11:151–162
Arnsten AF (2000) Through the looking glass: differential noradenergic
modulation of prefrontal cortical function. Neural Plast 7:133–146.
doi:10.1155/NP.2000.133
Arnsten AFT (2006) Fundamentals of attention-deficit/hyperactivity dis-
order: circuits and pathways. J Clin Psychiatry 67(Suppl 8):7–12
Arnsten AF, Goldman-Rakic PS (1985) Alpha 2-adrenergic mechanisms
in prefrontal cortex associated with cognitive decline in aged non-
human primates. Science 230:1273–1276
Arnsten AF, Goldman-Rakic PS (1990) Analysis of alpha-2 adrenergic
agonist effects on the delayed nonmatch-to-sample performance of
aged rhesus monkeys. Neurobiol Aging 11:583–590
Arnsten AF, Jentsch JD (1997) The alpha-1 adrenergic agonist,
cirazoline, impairs spatial working memory performance in aged
monkeys. Pharmacol Biochem Behav 58:55–59
Arnsten AF, Cai JX, Goldman-Rakic PS (1988) The alpha-2 adrenergic
agonist guanfacine improves memory in aged monkeys without
sedative or hypotensive side effects: evidence for alpha-2 receptor
subtypes. J Neurosci Off J Soc Neurosci 8:4287–4298
Arnsten AF, Steere JC, Jentsch DJ, Li BM (1998) Noradrenergic influ-
ences on prefrontal cortical cognitive function: opposing actions at
4014 Psychopharmacology (2015) 232:4005–4016
postjunctional alpha 1 versus alpha 2-adrenergic receptors. Adv
Pharmacol San Diego Calif 42:764–767
Arnsten AF, Mathew R, Ubriani R, Taylor JR, Li BM (1999) Alpha-1
noradrenergic receptor stimulation impairs prefrontal cortical cogni-
tive function. Biol Psychiatry 45:26–31
Arnsten AF, Scahill L, Findling RL (2007) alpha2-Adrenergic receptor
agonists for the treatment of attention-deficit/hyperactivity disorder:
emerging concepts f rom new data . J Chi ld Adolesc
Psychopharmacol 17:393–406. doi:10.1089/cap.2006.0098
Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF
(2000) The alpha-2A-adrenoceptor agonist, guanfacine, increases
regional cerebral blood flow in dorsolateral prefrontal cortex of
monkeys performing a spatial working memory task.
Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol
23:240–249. doi:10.1016/S0893-133X(00)00111-1
Bari A, Robbins TW (2013) Noradrenergic versus dopaminergic modu-
lation of impulsivity, attention and monitoring behaviour in rats
performing the stop-signal task: possible relevance to ADHD.
Psychopharmacology (Berl) 230(1):89–111
Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis
DJ et al (2004) Protein kinase C overactivity impairs prefrontal
cortical regulation of working memory. Science 306:882–884. doi:
10.1126/science.1100021
Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive
deficit caused by regional depletion of dopamine in prefrontal cortex
of rhesus monkey. Science 205:929–32
Cai JX, Ma YY, Xu L, Hu XT (1993) Reserpine impairs spatial working
memory performance in monkeys: reversal by the alpha 2-
adrenergic agonist clonidine. Brain Res 614:191–196
Carlson S, Tanila H, Rämä P, Mecke E, Pertovaara A (1992) Effects of
medetomidine, an alpha-2 adrenoceptor agonist, and atipamezole,
an alpha-2 antagonist, on spatial memory performance in adult and
aged rats. Behav Neural Biol 58:113–119
Chamberlain SR, Müller U, Blackwell AD, Robbins TW, Sahakian BJ
(2006) Noradrenergic modulation of workingmemory and emotion-
al memory in humans. Psychopharmacology 188:397–407
Coull JT, Middleton HC, Robbins TW, Sahakian BJ (1995) Contrasting
effects of clonidine and diazepam on tests of working memory and
planning. Psychopharmacology 120:311–321
Courtney SM, Petit L, Maisog JM, Ungerleider LG, Haxby JV (1998) An
area specialized for spatial working memory in human frontal cor-
tex. Science 279:1347–1351
De Luca CR, Wood SJ, Anderson V, Buchanan JA, Proffitt TM, Mahony
K et al (2003) Normative data from the CANTAB. I: development of
executive function over the lifespan. IJ Clin Exp Neuropsychol 25:
242–254. doi:10.1076/jcen.25.2.242.13639
Decamp E, Clark K, Schneider JS (2011) Effects of the alpha-2
adrenoceptor agonist guanfacine on attention and working memory
in aged non-human primates. Eur J Neurosci 34:1018–1022. doi:10.
1111/j.1460-9568.2011.07815.x
Doze VA, Papay RS, Goldenstein BL, Gupta MK, Collette KM, Nelson
BW et al (2011) Long-term α1A-adrenergic receptor stimulation
improves synaptic plasticity, cognitive function, mood, and longev-
ity. Mol Pharmacol 80(4):747–758
Dunnett SB (1990) Role of the prefrontal cortex and striatal output systems
in short-term memory deficits associated with aging, basal forebrain
lesions, and cholinergic-rich grafts. Can J Psychol 44:210–232
Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E
(1990) Central alpha 1-adrenergic stimulation in relation to the be-
haviour stimulating effect of modafinil; studies with experimental
animals. Eur J Pharmacol 180:49–58
Field A (2013) Discovering statistics using SPSS, 3rd edn. SAGE
Publications Ltd, London
Floresco SB, Seamans JK, Phillips AG (1997) Selective roles for hippo-
campal, prefrontal cortical, and ventral striatal circuits in radial-arm
maze tasks with or without a delay. J Neurosci 17(5):1880–1890
Franowicz JS, Arnsten AF (1998) The alpha-2a noradrenergic agonist,
guanfacine, improves delayed response performance in young adult
rhesus monkeys. Psychopharmacology (Berl) 136:8–14
Franowicz JS, Arnsten AFT (1999) Treatment with the noradrenergic
alpha-2 agonist Clonidine, but not Diazepam, improves spatial
working memory in normal young rhesus monkeys .
Neuropsychopharmacology 21:611–621
Funahashi S, Bruce CJ, Goldman-Rakic PS (1989) Mnemonic coding of
visual space in the monkey’s dorsolateral prefrontal cortex. J
Neurophysiol 61:331–349
Fuster JM, Alexander GE (1971) Neuron activity related to short-term
memory. Science 173:652–654
Fuster JM, Alexander GE (1973) Firing changes in cells of the nucleus
medialis dorsalis associated with delayed response behavior. Brain
Res 61:79–91
Horner AE, Heath CJ, Hvoslef-Eide M, Kent BA, Kim CH, Nilsson SR
et al (2013) The touchscreen operant platform for testing learning
and memory in rats and mice. Nat Protoc 8:1961–1984
Heidbreder CA, Groenewegen HJ (2003) The medial prefrontal cortex in
the rat: evidence for a dorso-ventral distinction based upon function-
al and anatomical characteristics. Neurosci & Biobeh Rev 27:555–
579
Hunt RD, Minderaa RB, Cohen DJ (1985) Clonidine benefits children
with attention deficit disorder and hyperactivity: report of a double-
blind placebo-crossover therapeutic trial. J Am Acad Child
Psychiatry 24:617–629
Jackson WJ, Buccafusco JJ (1991) Clonidine enhances delayed
matching-to-sample performance by young and aged monkeys.
Pharmacology Biochemistry and Behavior 39(1):79–84
Jäkälä P, RiekkinenM, Sirviö J, Koivisto E, Kejonen K,VanhanenM et al
(1999) Guanfacine, but not clonidine, improves planning and work-
ing memory performance in humans. Neuropsychopharmacology
20:460–470
Kubota K, Niki H (1971) Prefrontal cortical unit activity and delayed
alternation in monkeys. J Neurophysiol 34:337–347
Lapiz MDS, Morilak DA (2006) Noradrenergic modulation of cognitive
function in rat medial prefrontal cortex as measured by attentional
set shifting capability. Neuroscience 137(3):1039–1049
Li BM, Mei ZT (1994) Delayed-response deficit induced by local injec-
tion of the alpha 2-adrenergic antagonist yohimbine into the dorso-
lateral prefrontal cortex in young adult monkeys. Behav Neural Biol
62(2):134–139
Li BM, Mao ZM, Wang M, Mei ZT (1999) Alpha-2 adrenergic modula-
tion of prefrontal cortical neuronal activity related to spatial working
memory in monkeys. Neuropsychopharmacol Off Publ Am Coll
Neuropsychopharmacol 21:601–610. doi:10.1016/S0893-
133X(99)00070-6
Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M (1992) Role of
catecholamines in the modafinil and amphetamine induced wake-
fulness, a comparative pharmacological study in the cat. Brain Res
591:319–326
Luine V, Hearns M (1990) Spatial memory deficits in aged rats: contri-
butions of the cholinergic system assessed by ChAT. Brain Res 523:
321–324
Luine V, Bowling D, Hearns M (1990) Spatial memory deficits in aged
rats: contributions of monoaminergic systems. Brain Res 537:271–
278
Mao ZM, Arnsten AF, Li BM (1999) Local infusion of an alpha-1 adren-
ergic agonist into the prefrontal cortex impairs spatial workingmem-
ory performance in monkeys. Biol Psychiatry 46:1259–1265
McAllister KAL, Saksida LM, Bussey TJ (2013) Dissociation between
memory retention across a delay and pattern separation following
medial prefrontal cortex lesions in the touchscreen TUNL task.
Neurobiol Learn Mem 101:120–126. doi:10.1016/j.nlm.2013.01.
010
Psychopharmacology (2015) 232:4005–4016 4015
Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ,
Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian
BJ (2013) Effects of modafinil on non-verbal cognition, task enjoy-
men t and c rea t i ve th ink ing in hea l t hy vo lun t ee r s .
Neuropharmacology 64(1):490–495
Oomen CA, Hvoslef-Eide M, Heath CJ, Mar AC, Horner AE, Bussey TJ
et al (2013) The touchscreen operant platform for testing working
memory and pattern separation in rats and mice. Nat Protoc 8:2006–
2021
Oomen CA, Hvoslef-Eide M, Kofink D, Preusser F, Mar AC, Saksida
LM et al (2015) A novel 2- and 3-choice touchscreen-based contin-
uous trial-unique nonmatching-to-location task (cTUNL) sensitive
to functional differences between dentate gyrus and CA3 subregions
of the hippocampus. Psychopharmacology (Berl). doi:10.1007/
s00213-015-4019-6
Paxinos G, Watson C (2013) The rat brain in stereotaxic coordinates, 7th
edn. Elsevier Academic Press, London
Postle BR, Berger JS, Taich AM,D’EspositoM (2000) Activity in human
frontal cortex associated with spatial working memory and saccadic
behavior. J Cogn Neurosci 12(Suppl 2):2–14. doi:10.1162/
089892900564028
Rämä P, Linnankoski I, Tanila H, Pertovaara A, Carlson S (1996)
Medetomidine, atipamezole, and guanfacine in delayed response
performance of aged monkeys. Pharmacol Biochem Behav 55:
415–422
Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF (2006)
Alpha2A-adrenoceptor stimulation improves prefrontal cortical regula-
tion of behavior through inhibition of cAMP signaling in aging animals.
Learn Mem Cold Spring Harb N 13:770–776. doi:10.1101/lm.298006
Robbins TW, Arnsten AFT (2009) The neuropsychopharmacology of
fronto-executive function: monoaminergic modulation. Annu Rev
Neurosci 32:267–287. doi:10.1146/annurev.neuro.051508.135535
Scoriels L, Barnett JH, Soma PK, Sahakian BJ, Jones PB (2012) Effects
of modafinil on cognitive functions in first episode psychosis.
Psychopharmacology 220(2):249–258
Seamans JK, Floresco SB, Phillips AG (1995) Functional differences
between the prelimbic and anterior cingulate regions of the rat pre-
frontal cortex. Beh Neurosci 109(6):1063
Sirviö J, Harju M, Riekkinen P Jr., Haapalinna A, Riekkinen PJ (1992)
Comparative effects of alpha-2 receptor agents and THA on the
performance of adult and aged rats in the delayed non-matching to
position task. Psychopharmacology (Berl) 109:127–133
Stone EA, Cotecchia S, Lin Y, Quartermain D (2002) Role of brain alpha
1B-adrenoceptors inmodafinil-induced behavioral activity. Synap N
Y N 46:269–270. doi:10.1002/syn.10127
Swartz BE, McDonald CR, Patel A, Torgersen D (2008) The effects of
guanfacine on working memory performance in patients with
localization-related epilepsy and healthy controls. Clin
Neuropharmacol 31:251–260. doi:10.1097/WNF.0b013e3181633461
Talpos JC, McTighe SM, Dias R, Saksida LM, Bussey TJ (2010) Trial-
unique, delayed nonmatching-to-location (TUNL): a novel, highly
hippocampus-dependent automated touchscreen test of location
memory and pattern separation. Neurobiol Learn Mem 94:341–
352. doi:10.1016/j.nlm.2010.07.006
Tanila H, Rämä P, Carlson S (1996) The effects of prefrontal intracortical
microinjections of an alpha-2 agonist, alpha-2 antagonist and lido-
caine on the delayed alternation performance of aged rats. Brain Res
Bull 40:117–119
Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian
BJ, Müller U (2010) Effects of modafinil and prazosin on cognitive
and physiological funct ions in heal thy volunteers . J
Psychopharmacol Oxf Engl 24:1649–1657. doi:10.1177/
0269881109105899
Zarahn E, Aguirre GK, D’Esposito M (1999) Temporal isolation of the
neural correlates of spatial mnemonic processing with fMRI. Brain
Res Cogn Brain Res 7:255–268
Zhang Z, Cordeiro Matos S, Jego S, Adamantidis A, Séguéla P (2013)
Norepinephrine drives persistent activity in prefrontal cortex via
synergistic α1 and α2 adrenoceptors. PloS One 8, e66122. doi:10.
1371/journal.pone.0066122
4016 Psychopharmacology (2015) 232:4005–4016
